• br Platinum Priority Prostate Cancer Editor s Choice br Edit

  2019-09-23

  

  Platinum Priority – Prostate Cancer – Editor’s Choice Editorial by Gunnar Steineck, Olof Akre and Anna Bill-Axelson on pp. 52–53 of this Ac-DEVD-CHO issue A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer Jonas Hugosson a,[1T$DIF]*, Monique J. Roobol b,

• br The approach for evaluating ALNs in breast cancer

  2019-09-23

  

  The approach for evaluating ALNs in breast cancer has changed over the years. In the early 1990s, ALN dissection (ALND) was the only way to discover and manage metastatic ALNs.4 Subsequently, sentinel LN biopsy (SLNB) became a standard method for evaluation of ALNs.5,6 More recently, several surge

• br mRNAs were quantified with

  2019-09-16

  

  mRNAs were quantified with real-time quantitative Lovastatin using Power SybrGreen® Master Mix (Applied Biosystems) and gene-specific primers described in Table 1. Commercially available primers (Qiagen, Hilden, Germany) were used to quantify BCL2 (Hs_BCL2-1-SG Quanti-Tect Primer #249900), ESR1 (

• br Biodistribution studies br Biodistribution results of F F

  2019-09-16

  

  3.6. Biodistribution studies Biodistribution results of [18F]FPTT were shown in Fig. 5. At 1 h p.i., the uptakes in uterus and ovary of female SD rats that had been estrogen Fig. 3. Representative PET images of [18F]FPTT in PR-positive MCF-7 (A) and PR-negative MDA-MB-231 (B) tumors in tumor

• br Methods and Materials CRT

  2019-09-16

  

  Methods and Materials: 36 CRT treated anal cancer patients with 18F-FDG PET/CT scans 2 weeks pre-and 6-16 weeks post-CRT. CBC with differential within 2 weeks from, weekly during, and 2 week post treatment were obtained. HT was defined as baseline CBC change to nadir, and post-treatment recovery.

• LOXO-101 Number of tissue and plasma samples obtained at eac

  2019-09-02

  

  Number of tissue and plasma samples obtained at each time point are described in Fig. 1. One tumor tissue specimen did not contain tumor LOXO-101 so we analyzed 56 samples. During the first 12 weeks of treatment, about 90% of planned plasma samples were collected. At 24 weeks, 40 plasma samples were

• Knockdown of XIAP repressed lung cancer development and prom

  2019-09-02

  

  Knockdown of XIAP repressed lung cancer development and promoted apoptosis [38]. XIAP silencing activated the cleavage cascade of caspase-3 or -9 that promoted PARP signaling in NSCLC [39]. Overexpression of miR-CHA1 directly suppressed XIAP expression, resulting in cleaved caspase-3 and PARP. miR-C

• FF-MAS br Disclaimer br Author declaration br Introduction I

  2019-08-26

  

  Disclaimer Author declaration Introduction Immune checkpoint inhibitors represent an important development in the treatment of advanced cancers. In cases of non-small cell lung cancer (NSCLC), the effectiveness of anti-programmed cell death-1 (PD-1) antibody therapies such as nivolumab [1]

• Based on proof of concept gained

  2019-08-26

  

  Based on proof-of-concept gained form our previous preclinical study [11], the patients with T790 M Fluxametamide possibly responded to the combination of afatinib and ruxolitinib better than the patients without T790 M mutations. However, the clinical efficacy was not different according to the ex

• Previous prostate cancer incidence projections estimated tha

  2019-08-20

  

  Previous prostate cancer incidence projections estimated that the incidence rates will remain stable from the period of 2003–2007 to 2028–2032 at 123.3/100,000 [3]. However, these projections are based on a long-term projection of constant rates, since the authors of the previous projections were un

• However the diagnostic misclassification of STS might be

  2019-08-16

  

  However, the diagnostic misclassification of STS might be another explanation for differences between AIRTUM and RARECAREnet data, considering that diagnostic discrepancy between pathologists may occur in up to 30% of cases [4]. Additionally, some of this difference may have resulted from variation

• Prostaglandin J2 Our results are consistent with

  2019-08-16

  

  Our results are consistent with results from simulation studies that pointed out that estimates are not influenced noticeably by the number of knots, as long as a sensible number of knots is selected [13,14]. In large datasets, the AIC and BIC will select models with high df when a lower value for t

• Results br Discussion As reported in other settings a decrea

  2019-08-16

  

  Results Discussion As reported in other settings, a decrease in overall incidence and mortality rates for HNC was observed [31]. However, the overall ASIR and ASMR for AGC increased. We hypothesise that trends for HNC are related to the declines in tobacco smoking as a result of the anti-tobacco

• br Discussion Due to the

  2019-08-16

  

  Discussion Due to the lack of current publicly available interactive web-tools for communicating risk, there is very little literature on the efficacy of web-based interactive graphics on the improvement in the understanding of risk [27]. Therefore, due to the lack of qualitative studies that add

• br Discussion The demographic and clinical characteristics o

  2019-08-16

  

  Discussion The demographic and clinical characteristics of the assessed episodes are mostly consistent with the literature, particularly concerning patients’ age, neoplasm location and proportion of BCC and SCC [18,19]. However, for individual patients, the ratio NMSC:MM observed (7:1) was low, w

100 records 6/7 page Previous Next First page 上5页 67